Heather Landau, MD

Heather J. Landau, MD, discusses the most exciting outcomes observed in a trial of BCMA-targeted NXC-201 for light chain amyloidosis.

Heather J. Landau, MD, discusses results from a trial of the investigational CAR T-cell therapy NXC-201 in relapsed/refractory AL amyloidosis.

Heather J. Landau, MD, discussed promising results of CAR T-cell therapy in light chain amyloidosis and the challenge of developing trials for this rare plasma cell disorder.